- Home
- HAFN vs CPRX Comparison
HAFN vs CPRX Comparison
Compare HAFN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- CPRX
- Stock Information
- Founded
- HAFN 2012
- CPRX 2002
- Country
- HAFN Singapore
- CPRX United States
- Employees
- HAFN N/A
- CPRX N/A
- Industry
- HAFN
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- CPRX Health Care
- Exchange
- HAFN Nasdaq
- CPRX Nasdaq
- Market Cap
- HAFN 2.7B
- CPRX 2.9B
- IPO Year
- HAFN N/A
- CPRX 2006
- Fundamental
- Price
- HAFN $5.19
- CPRX $21.46
- Analyst Decision
- HAFN Strong Buy
- CPRX Strong Buy
- Analyst Count
- HAFN 1
- CPRX 6
- Target Price
- HAFN $6.50
- CPRX $32.83
- AVG Volume (30 Days)
- HAFN 1.5M
- CPRX 1.4M
- Earning Date
- HAFN 08-27-2025
- CPRX 08-06-2025
- Dividend Yield
- HAFN 17.59%
- CPRX N/A
- EPS Growth
- HAFN N/A
- CPRX 178.13
- EPS
- HAFN 1.20
- CPRX 1.57
- Revenue
- HAFN $2,631,664,000.00
- CPRX $534,645,999.00
- Revenue This Year
- HAFN N/A
- CPRX $16.37
- Revenue Next Year
- HAFN $1.88
- CPRX $8.80
- P/E Ratio
- HAFN $4.08
- CPRX $13.68
- Revenue Growth
- HAFN N/A
- CPRX 29.97
- 52 Week Low
- HAFN $3.61
- CPRX $14.97
- 52 Week High
- HAFN $8.34
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- CPRX 32.68
- Support Level
- HAFN N/A
- CPRX $20.95
- Resistance Level
- HAFN N/A
- CPRX $22.07
- Average True Range (ATR)
- HAFN 0.00
- CPRX 0.63
- MACD
- HAFN 0.00
- CPRX -0.20
- Stochastic Oscillator
- HAFN 0.00
- CPRX 17.23
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).